.jpg)
Sayre Therapeutics with a portfolio of oncology and immunology focussed commercial products, has entered into an exclusive license agreement with GP Pharm S.A to distribute, market and sell Lutrate Depot in 1 and 3 month formulations in India, Sri Lanka, Bangladesh and Nepal. GP Pharm will supply Lutrate to Sayre on an exclusive basis from its manufacturing facility in Barcelona, Spain
According to Vandana Subramanian, Senior Vice-President, BD & Corporate Strategy, Sayre Therapeutics' collaboration with GP Pharm would help bring an EMA approved best-in-class differentiated Leuprolide Acetate depot formulation to South Asia.
“This medicine provides a further fillip to our efforts to build a portfolio for oncology diseases with advanced options for patients suffering from prostate cancer. Lutrate will greatly benefit the South Asian patient community and improve their quality of life,” she added.
“We are extremely pleased that we have been able to expand the availability of Lutrate to the SouthAsian region. This collaboration represents one step further in our worldwide expansion and it will allow us to position, said Dr. Antonio Parente, Executive President, GP Pharm.
While GP Pharm S.A. is a privately owned Spanish Biopharmaceutical Company located in Barcelona, (Spain and founded in 2000, the two-year old Sayre Therapeutics is South Asia’s only integrated platform for disease management backed by a distribution and commercialization model for novel drugs, companion diagnostics and drug-delivery devices in oncology and immunology.
Sayre therapeutics, lutrate depot license pact, gp pharm s.a, sri lanka, bangladesh and nepal
